Vertex's non-opioid neuropathic pain treatment succeeds in mid-stage trial

 Vertex Pharmaceuticals said on Wednesday its drug, VX-548, was successful in reducing nerve pain in patients in a mid-stage trial.

Treatment with the drug resulted in a statistically significant reduction in weekly average of daily pain intensity, as measured on a scale at 12 weeks.

The trial studied the non-opioid pain drug in patients with diabetic peripheral neuropathy, a type of nerve damage caused by high blood sugar

https://finance.yahoo.com/news/1-vertexs-non-opioid-neuropathic-114932027.html